Scarica l'app Stockscreener
1,004.92
0.18%
-1.78
Dopo l'orario di chiusura:
1003.69
-1.23
-0.12%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché LLY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$1,006.70
Aprire:
$1006.98
Volume 24 ore:
2.78M
Relative Volume:
0.91
Capitalizzazione di mercato:
$896.13B
Reddito:
$72.25B
Utile/perdita netta:
$25.28B
Rapporto P/E:
36.17
EPS:
27.781
Flusso di cassa netto:
$10.37B
1 W Prestazione:
+5.95%
1M Prestazione:
+11.04%
6M Prestazione:
-1.99%
1 anno Prestazione:
+37.04%
Intervallo 1D:
$997.41
$1,014.38
Intervallo di 1 settimana:
$943.26
$1,022.82
Portata 52W:
$623.78
$1,133.95
Lilly Eli Co Stock (LLY) Company Profile
Nome
Lilly Eli Co
Settore
Industria
Telefono
(317) 276-2000
Indirizzo
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY vs JNJ, ABBV, NVS, AZN
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,004.92 | 897.72B | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
226.71 | 555.59B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
210.39 | 372.39B | 62.82B | 3.60B | 19.98B | 2.0274 |
NVS
Novartis Ag Adr
|
148.08 | 285.77B | 54.66B | 13.58B | 16.05B | 7.0171 |
AZN
Astrazeneca Plc
|
181.58 | 286.84B | 60.48B | 10.40B | 8.05B | 3.3297 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-17 | Downgrade | HSBC Securities | Hold → Reduce |
| 2026-02-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-16 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2025-12-15 | Reiterato | BofA Securities | Buy |
| 2025-12-15 | Reiterato | Goldman | Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-11-10 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-10-20 | Reiterato | BMO Capital Markets | Outperform |
| 2025-10-14 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-09-17 | Downgrade | Berenberg | Buy → Hold |
| 2025-08-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2025-08-18 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-08-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-06-05 | Downgrade | Erste Group | Buy → Hold |
| 2025-04-28 | Downgrade | HSBC Securities | Buy → Reduce |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-09-13 | Ripresa | Citigroup | Buy |
| 2024-08-12 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2024-02-21 | Downgrade | DZ Bank | Buy → Hold |
| 2024-02-16 | Reiterato | Morgan Stanley | Overweight |
| 2023-12-21 | Downgrade | Daiwa Securities | Buy → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-10-20 | Ripresa | UBS | Buy |
| 2023-08-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-07-26 | Reiterato | Citigroup | Buy |
| 2023-07-14 | Iniziato | HSBC Securities | Buy |
| 2023-05-24 | Reiterato | BofA Securities | Buy |
| 2023-05-24 | Reiterato | UBS | Buy |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-02-15 | Downgrade | Societe Generale | Hold → Sell |
| 2022-11-18 | Iniziato | Credit Suisse | Outperform |
| 2022-09-22 | Aggiornamento | UBS | Neutral → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Outperform |
| 2022-04-06 | Ripresa | Morgan Stanley | Overweight |
| 2022-03-10 | Iniziato | Daiwa Securities | Outperform |
| 2022-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2022-01-03 | Reiterato | Bernstein | Mkt Perform |
| 2021-12-17 | Iniziato | Goldman | Neutral |
| 2021-12-16 | Reiterato | BMO Capital Markets | Outperform |
| 2021-12-16 | Reiterato | BofA Securities | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-10-11 | Aggiornamento | Berenberg | Hold → Buy |
| 2021-09-29 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-08-05 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-06-24 | Reiterato | Cantor Fitzgerald | Overweight |
| 2021-01-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2020-12-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-09-29 | Iniziato | Berenberg | Hold |
| 2020-09-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-06-16 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-04-21 | Downgrade | UBS | Buy → Neutral |
| 2020-04-09 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-02-06 | Iniziato | Mizuho | Neutral |
| 2019-12-18 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-04-24 | Aggiornamento | Edward Jones | Hold → Buy |
| 2019-04-11 | Downgrade | Guggenheim | Buy → Neutral |
| 2019-03-12 | Iniziato | JP Morgan | Overweight |
| 2019-01-23 | Iniziato | UBS | Buy |
| 2018-11-26 | Downgrade | Citigroup | Buy → Neutral |
| 2018-10-31 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2018-10-09 | Iniziato | Guggenheim | Buy |
| 2018-10-01 | Reiterato | SunTrust | Buy |
| 2018-09-26 | Ripresa | JP Morgan | Overweight |
Mostra tutto
Lilly Eli Co Borsa (LLY) Ultime notizie
Caitlin Clark Foundation & Eli Lilly launch three Indy community courts - WISH-TV
Eli Lilly and Co stock (US5324571083): obesity drug momentum after strong Q1 surge - AD HOC NEWS
Eli Lilly and Company (LLY): Investors Advised to Focus on the Bigger Picture - Insider Monkey
Caitlin Clark helps bring new youth sports courts to Indianapolis - Stock Titan
Is Kailera Therapeutics a Buy After Its Sizzling IPO? - The Motley Fool
Eli Lilly Stock (LLY) Opinions on Healthcare Sector Strength - Quiver Quantitative
Eli Lilly (LLY) Reports New Late-Stage Weight Loss Trial Results - Insider Monkey
Novo Nordisk A/S Stock (NVO) Moved Down by 3.09% on May 15: Drivers Behind the Movement - TradingKey
Editorial: Lilly earns kudos for 150 years of innovation, economic impact - Indianapolis Business Journal
Weekly Buzz: Lilly Posts Positive Trial Data, Rigel Licenses PROTAC Drug, BMY Strikes $15.2B Deal - RTTNews
Can Eli Lilly Benefit From Russell 1000 Healthcare Demand? - Kalkine Media
Analyst Raises Eli Lilly (LLY) Price Target by $52 Following Q1 Report - Insider Monkey
Byron Donalds trades in Chipotle, Eli Lilly, Intuit, and Marvell Technology stocks - Investing.com Canada
Eli Lilly & Co. stock (US5324571083): Q1 2026 earnings beat and guidance hike keep obesity boom stor - AD HOC NEWS
NVO Stock Pops Premarket: Novo Nordisk Unveils Fresh Wegovy Data That Could Narrow Eli Lilly’s Obesity Lead - Stocktwits
Eli Lilly Growth Story Keeps S&P 500 Index Momentum Alive - Kalkine Media
Eli Lilly Growth Story Keeps S&P 500 Index In Focus - Kalkine Media
Jim Cramer Sees a ‘Bull Market’ for Eli Lilly Stock (LLY) - TipRanks
Is Eli Lilly Going To $1,100? - 24/7 Wall St.
Jim Cramer Believes “It Is a Bull Market for Eli Lilly” - Insider Monkey
Eli Lilly’s New Alopecia Drug Trial Moves Forward, Expanding Its Immunology Pipeline - TipRanks
Lilly’s Brenipatide IBS-C Trial Advances: What Investors Should Watch - TipRanks
BMO Capital Sticks to Their Buy Rating for Eli Lilly & Co (LLY) - The Globe and Mail
Lilly announces $50M contribution to UNICEF USA for children’s health - Indianapolis Business Journal
Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? - AOL.com
Lilly GLP-1 pill can keep weight off after stopping jabs, study finds - Chemist+Druggist
Eli Lilly & Co. stock (US5324571083): Q1 earnings beat with 55% revenue surge - AD HOC NEWS
Checkmate for Cancer: What Eli Lilly and Bayer Can Learn from Vidac Pharma - news.financial
Can Novo Nordisk close the gap to Eli Lilly? - Investors' Chronicle
Eli Lilly brings monthly Alzheimer's therapy donanemab to India at ₹91,688 per vial - The Economic Times
Why is Eli Lilly stock rallying today? By Investing.com - Investing.com South Africa
Why is Eli Lilly stock rallying today? - Investing.com
Eli Lilly stock advances as Lormalzi (donanemab) launch in India boosts sentiment - Traders Union
Eli Lilly (LLY) Launches Alzheimer's Therapy Lormalzi in India - GuruFocus
HIMS Stock Crashes Overnight After Brutal Q1 — But An Investor Says Novo, Lilly Deals Could Make It ‘Netflix Of Healthcare’ - Stocktwits
Eli Lilly & Co. stock (US5324571083): Strong Q1 earnings beat and raised FY2026 guidance - AD HOC NEWS
Jim Cramer’s Take on 24 Stocks: Cisco, Eli Lilly, and Ford - Insider Monkey
Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss - Benzinga
Novo, Lilly tout respective early response and weight loss maintenance data as GLP-1 rivalry intensifies - Fierce Pharma
Encouraging Results for Eli Lilly's Orforglipron in Weight Loss Trials - GuruFocus
Lilly CEO David Ricks keeps eye on future while company celebrates history - Indianapolis Business Journal
BMO reiterates Eli Lilly stock Outperform on maintenance data - Investing.com
Parkland School Board tables vote on tax break for Eli Lilly - The Morning Call
Eli Lilly stock (US5324571083): Long-term weight loss trial success boosts obesity drug prospects - AD HOC NEWS
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,300 - Moomoo
Gut Bugs and Lilly’s Foundayo Both Help Curb Yo-Yo Diet Effect - Bloomberg.com
Eli Lilly on big upswing in research as Indy company marks 150 years - AOL.com
Eli Lilly Launches Alzheimer's Drug Lormalzi Priced At Rs 91,688 Per Vial In India - NDTV
Zacks Investment Ideas feature highlights Eli Lilly, Novo, JP Morgan, Coca-Cola, PepsiCO and Mondelez - Yahoo Finance
Eli Lilly launches Alzheimer’s drug in India at $957 per vial - Investing.com Nigeria
Eli Lilly launches Alzheimer’s drug in India at $957 per vial By Investing.com - Investing.com South Africa
Lilly Eli Co Azioni (LLY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):